Inhibiting downstream targets such as Survivin, C-Myc, Cyclin D1, and others by LLL12B, is likely one of the main mechanisms of sensitizing ovarian cancer cells to cisplatin or paclitaxel and likely one the main mechanisms of synergism by drug combination. This evidence concerns the gene BIRC5 and ovarian carcinoma.